BioSpace News Archive

Well-established Mouse Model Utilizes T-cell-depleted, Mismatched Donor Bone Marrow Transplants in Conjunction with Veto T-cell Transplants to Correct Sickle Cell Disease with Minimal Risk as Reported in Bone Marrow Transplantation ( BMT) Journal

Alzamend Neuro®, Inc. (“ Alzamend ”) today announced that it has entered into a securities purchase agreement with Digital Power Lending, LLC (“ DPL ”), a wholly owned subsidiary of Ault Global Holdings, Inc. (“ AGH ”), a related party. Pursuant to the securities purchase agreement, DPL agreed to invest an aggregate of $10,000,000 in our common stock and warrants.

-- Received FDA approval of sNDAs for both VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsule -- -- U.S. commercial launch of VAZALORE planned for third quarter 2021 -- -- Secured $63 million of gross proceeds in an underwritten public offering of common stock for the launch of VAZALORE

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2020 financial results on Wednesday, March 17, 2021 , after the close of the U.S. financial markets. Following the announcement, members of the management team will host a conference call and webcast

Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing. The proceeds will be used to advance its lead development candidate into the clinic, accelerate pipeline growth and bolster its platform capabilities to rationally design and develop small molecule degraders (also known a

- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease Selected for Oral and Late-breaking Presentations -

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Precision for Medicine, a specialized services company supporting next generation approaches to drug development and commercialization, today announce that they will present data on a) the development of a novel flow immunophenotyping assay to accurately evaluate total PD-1

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 25, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2020 and to provide a business update.

Retia Medical (https://www.retiamedical.com/) announced today the publication of a new study validating the performance of its Multi-Beat Analysis (MBA™) algorithm in tracking changes in cardiac output (CO) caused by different fluid and drug interventions.

InDex Pharmaceuticals Holding AB announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021.